Compare BioNano Genomics Inc (BNGO) vs Essex Property Trust, Inc. (ESS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Essex Property Trust, Inc. — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Essex Property Trust, Inc. trades at $297.8 (market cap $19.16B). The key difference: Essex Property Trust, Inc. is far larger — about 1451.5× BioNano Genomics Inc's market cap, and Essex Property Trust, Inc. pays a 3.47% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | ESS | |
|---|---|---|
Market Cap | $13.20M | $19.16B |
Sector | Health | Real Estate |
52-Week High | $4.92 | $298.33 |
52-Week Low | $1.09 | $239.61 |
Enterprise Value | $15.81M | $25.88B |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
ESS trades at $297.48, up 1.34% today, near its consensus price target of $294.25. The stock shows bullish technical momentum with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent news highlights include the upcoming Q2 2026 earnings release and the company's addition to the Russell Microcap Index. Fundamentals remain solid with $1.89B revenue and a 30.03% net income margin in 2025.
Outlook is cautiously optimistic given analyst consensus leaning toward Hold (52.17%) despite recent beats. Key opportunities include AI-driven rental demand in West Coast markets and a sustainable dividend. Risks involve high debt levels (debt-to-asset ratio of 51.92% in 2024) and potential economic sensitivity. The stock offers moderate upside if earnings momentum continues but requires monitoring of leverage and regional market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →
